Helixmith Co

Helixmith Co Equity

The The Equity of Helixmith Co (084990.KQ) as of Oct 21, 2026 is 141.98 B KRW. In the previous year, The Equity was 142.47 B KRW — a change of -0.34% (lower).

Equity

141.98 BKRW

YoY

-0.34%

Last updated:

In 2025, Helixmith Co's equity was 141.98 B KRW, a -0.34% increase from the 142.47 B KRW equity in the previous year.

The Helixmith Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
133.87 B KRW
Jan 1, 2019
195.57 B KRW
Jan 1, 2020
276.30 B KRW
Jan 1, 2021
225.35 B KRW
Jan 1, 2022
216.80 B KRW
Jan 1, 2023
154.14 B KRW
Jan 1, 2024
142.47 B KRW
Jan 1, 2025
141.98 B KRW
The Helixmith Co Equity history
YEAREquityYoY
141.98 BKRW-0.34%
142.47 BKRW-7.57%
154.14 BKRW-28.90%
216.80 BKRW-3.79%
225.35 BKRW-18.44%
276.30 BKRW+41.28%
195.57 BKRW+46.09%
133.87 BKRW-18.60%
164.45 BKRW-3.79%
170.93 BKRW+154.37%
67.20 BKRW+0.20%
67.06 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Helixmith Co Stock analysis

What does Helixmith Co do? Helixmith Co., Ltd. generates revenue through its Natural Products Business segment, which develops and sells raw materials for functional materials and health functional foods under brands like Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment focuses on developing treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer therapies. Customers include companies in the health and pharmaceutical sectors seeking natural ingredients and specialized medical treatments. The company serves two distinct market segments: one for natural product raw materials and another for advanced biopharmaceutical solutions. The Natural Products Business segment targets clients requiring raw materials for functional materials and health functional foods, leveraging branded products Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment caters to healthcare providers and pharmaceutical firms developing treatments for specific medical conditions, including diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer applications. Both segments operate within the broader health and biotechnology industries, with the company's revenue streams derived from product sales across these specialized markets. Helixmith Co., Ltd. monetizes its research and development efforts through the commercialization of natural substance-based raw materials and biopharmaceutical treatments. The company's product portfolio includes Alex, Murphine, and Nimosin for the natural products market, while its biopharmaceutical segment offers treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer conditions. Revenue is generated from direct sales to businesses in the health, functional food, and pharmaceutical sectors, with no mention of additional revenue streams such as licensing or partnerships. Helixmith Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Helixmith Co's Equity

Helixmith Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Helixmith Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Helixmith Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Helixmith Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Helixmith Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Helixmith Co stock

The Equity of Helixmith Co is 141.98 B KRW in 2025.

The Equity of Helixmith Co changed from 142.47 B KRW to 141.98 B KRW, representing a -0.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Helixmith Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Helixmith Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Helixmith Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Helixmith Co